Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3964)	1/18/1998 12:16:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 9719

Cultures do change. They hired a guy named Steve Carroll. Hard working and relatively apolitical, he's hung through the garbage and is largely responsible for making BPI work. BPI was brought to XOMA by Glenn Nedwin, the CEO of Incyte's precursor company, a spinoff from the Monsanto spinoff, In Vitron. Glenn did a stint as V.P., Business Development at XOMA. Any success at XOMA would largely result from the efforts of these two and hard workers like Butch Dellio and a devoted technical staff. A generation of investors has gotten screwed, while exercise prices on options have been lowered and deals have been cut for off-shore placements. Not sure that it should be legal to do such, but they've kept the ball in the air, at the expense of their shareholders, through all of the lousy projects and failed clinicals. I haven't read the recent releases. The XOMA Red Flag (TM) is characterized by a release where current results are described as promising, there is a statement from Pat Scannon relating to current results, no statistics are given, and - here's the clincher - the last paragraph of the release is devoted to the next products in the pipeline.